Featured Research

from universities, journals, and other organizations

A Debate On Smokeless Tobacco

Date:
July 4, 2007
Source:
Public Library of Science
Summary:
In a debate in this week's PLoS Medicine, public health researchers discuss whether or not the public should be informed that using oral, smokeless tobacco (Swedish snus) is less hazardous to health than smoking tobacco.

Should the health community promote smokeless tobacco (snus) as a harm reduction measure?

In a debate in this week's PLoS Medicine, public health researchers discuss whether or not the public should be informed that using oral, smokeless tobacco (Swedish snus) is less hazardous to health than smoking tobacco.

Arguing the case for providing such information, Carol Gartner and Wayne Hall (University of Queensland, Australia) point to the Swedish experience. Snus seems to be widely used as an alternative to cigarettes in Sweden, contributing to the low overall prevalence of smoking and smoking-related disease. "On the Swedish experience," say Gartner and Hall, "there is a strong prima facie case on public health and ethical grounds for recommending snus to inveterate smokers who want to reduce their health risks and for considering public policies, such as lower taxes for snus and public information campaigns, to promote its use by smokers."

However, Simon Chapman and Becky Freedman (University of Sydney, Australia) argue that Sweden's experience is likely to be specific to that culture and not transferable to other settings, and that if tobacco companies are allowed to market snus they will undoubtedly use the opportunity to promote tobacco as well. "Snus enthusiasts in the public health community," say Chapman and Freedman, "focus on snus' potential to take people away from smoking. However transnational tobacco companies are already marketing snus using slogans that mention smoking, such as: 'When you can't smoke, snus.'"

Citation: Gartner CE, Hall WD, Chapman S, Freeman B (2007) Should the health community promote smokeless tobacco (snus) as a harm reduction measure? PLoS Med 4(7): e185


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Cite This Page:

Public Library of Science. "A Debate On Smokeless Tobacco." ScienceDaily. ScienceDaily, 4 July 2007. <www.sciencedaily.com/releases/2007/07/070703172903.htm>.
Public Library of Science. (2007, July 4). A Debate On Smokeless Tobacco. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2007/07/070703172903.htm
Public Library of Science. "A Debate On Smokeless Tobacco." ScienceDaily. www.sciencedaily.com/releases/2007/07/070703172903.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins